Synthetic Biologics to Report Third Quarter 2014 Financial Results
-- Conference Call Scheduled for Friday, November 14, 2014, at 8:30 a.m. EST --
ROCKVILLE, Md., Nov. 6, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that it intends to release its financial results for the three and nine months ended September 30, 2014 on Friday, November 14, 2014. The Company will hold an investor conference call on Friday, November 14th, at 8:30 a.m. EST.
During the call, Jeffrey Riley, Synthetic Biologics' Chief Executive Officer, will provide an update on the Company's C. difficile, C-IBS and Pertussis programs, and a review of upcoming milestones for the Phase 2 Trimesta™ program for the treatment of relapsing-remitting multiple sclerosis (MS). C. Evan Ballantyne, Synthetic Biologics' Chief Financial Officer, will review the Company's financial results for the three and nine months ended September 30, 2014.
Interested parties should call 1-888-347-5280 (U.S. toll free), 1-855-669-9657 (Canada toll free), or +1 412-902-4280 (International), fifteen minutes before the start of the call to register. Registered callers on the toll free line may ask to be placed in the queue for the Question & Answer Session. The call will also be webcast over the Internet at http://www.videonewswire.com/event.asp?id=100975. If you are unable to participate during the live conference call, the webcast will be available for replay at the same URL, http://www.videonewswire.com/event.asp?id=100975, for 30 days after the call.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage biotechnology company developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome. The Company is developing an oral biologic to protect the gastrointestinal (GI) microflora from the effects of intravenous (IV) antibiotics for the prevention of C. difficile infection, an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS) and a monoclonal antibody combination for the treatment of Pertussis. In addition, the Company is developing a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.
SOURCE Synthetic Biologics, Inc.
Released November 6, 2014